2019
Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease
Landau SI, Guo X, Velazquez H, Torres R, Olson E, Garcia-Milian R, Moeckel GW, Desir GV, Safirstein R. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney International 2019, 95: 797-814. PMID: 30904067, PMCID: PMC6543531, DOI: 10.1016/j.kint.2018.11.042.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseaseKidney injuryCisplatin-induced chronic kidney diseaseCisplatin-induced acute kidney injuryToll-like receptor 2Regulated necrosis pathwaysReversible kidney injuryAcute kidney injuryChronic kidney injuryProximal tubular damageKidney injury markersDoses of cisplatinEvidence of fibrosisMechanisms of progressionEffective chemotherapeutic agentWestern blot analysisFirst doseInjury markersIntraperitoneal cisplatinSignificant nephrotoxicityTubular damageKidney functionSecond doseCisplatin administration
2008
Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease
Desir GV. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Current Opinion In Nephrology & Hypertension 2008, 17: 181-185. PMID: 18277152, DOI: 10.1097/mnh.0b013e3282f521ba.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseaseBlood pressureAnimal modelsCardiac functionEnd-stage renal diseaseRegulation of renalaseSalt-dependent hypertensionDevelopment of hypertensionSystolic blood pressurePlasma renalaseRenalase deficiencyCatecholamine administrationSympathetic toneRenal diseaseKidney functionSubtotal nephrectomyPlasma catecholaminesCardiovascular diseaseHypertensionLower plasmaRenalaseCatecholaminesDiseaseAbnormalities